FDA Approves Fintepla For Treatment Of Dravet Syndrome
The US Food and Drug Administration has approved Fintepla (fenfluramine), a Schedule IV controlled substance, for the treatment of seizures associated with Dravet syndrome in patients 2 years of age…
Share